A Phase II randomized, placebo controlled, double-blind, multi-centre study to assess safety and efficacy of incremental doses of QGC001 in patients with NYHA class II/III chronic heart failure with left ventricular systolic dysfunction Short title: QUantum genomics Incremental Dosing in Heart Failure Acronym “QUID-HF”

Trial Profile

A Phase II randomized, placebo controlled, double-blind, multi-centre study to assess safety and efficacy of incremental doses of QGC001 in patients with NYHA class II/III chronic heart failure with left ventricular systolic dysfunction Short title: QUantum genomics Incremental Dosing in Heart Failure Acronym “QUID-HF”

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs Firibastat (Primary)
  • Indications Chronic heart failure
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms QUID-HF
  • Sponsors Quantum Genomics
  • Most Recent Events

    • 05 Mar 2018 was According to a Quantum Genomics media release, this trial was the subject of an amendment at the start of the year that widened the target patient profile to simplify and accelerate recruitment.
    • 24 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
    • 24 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top